Patients

Globally, 400-500 million people are affected by allergic rhinitis, and 10-20% of these have symptoms which are not well controlled. People who experience insufficient effect from symptomatic medication can benefit from allergy immunotherapy.

The most important difference between allergy immunotherapy treatment and treatments that only suppress allergy symptoms for a short time is that immunotherapy reprogrammes the body to induce immunological tolerance, thus altering the course of the disease.